Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Change in Accured Expenses (2021 - 2025)

PAVmed (PAVM) has 5 years of Change in Accured Expenses data on record, last reported at -$116000.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses changed N/A year-over-year to -$116000.0; the TTM value through Sep 2025 reached $771000.0, changed N/A, while the annual FY2024 figure was -$304000.0, 110.86% down from the prior year.
  • Change in Accured Expenses reached -$116000.0 in Q3 2025 per PAVM's latest filing, down from $493000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.6 million in Q4 2021 and bottomed at -$1.6 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $290055.6, with a median of $208000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: surged 18066.67% in 2023, then plummeted 255.84% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.6 million in 2021, then plummeted by 70.57% to $775000.0 in 2022, then soared by 31.48% to $1.0 million in 2023, then plummeted by 37.78% to $634000.0 in 2024, then tumbled by 118.3% to -$116000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$116000.0 in Q3 2025, $493000.0 in Q2 2025, and -$240000.0 in Q1 2025.